- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Rigel Pharmaceuticals Inc(RIGL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RIGL
11/13/2026: RIGL (2-star) is a SELL. SELL for 5 days. Simulated Profits (-10.70%). Updated daily EoD!
Rigel Pharmaceuticals is a commercial-stage biotechnology company that markets small-molecule therapies for immunology and oncology. The company's core strengths lie in its proven ability to navigate regulatory hurdles and successfully launch commercial products, specifically TAVALISSE and REZLIDHIA. The primary investment story centers on the continued market adoption of its dual-product portfolio and the potential for long-term growth through pipeline expansion. Key risks include intense competition from larger pharmaceutical incumbents, product concentration, and the ongoing need for effective execution to reach sustainable profitability. This stock may suit growth-oriented investors with a high risk tolerance who are interested in the biotechnology sector's commercial development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential through product adoption, though it carries high execution risk. |
| Momentum investor | Mixed fit | Momentum is highly conditional on positive clinical data or earnings surprises. |
| Value investor | Weak fit | Valuation is difficult to anchor given the company's early commercial stage and R&D-heavy business model. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses capital on growth. |
| Low-risk investor | Weak fit | High volatility inherent in biotechnology stocks makes this unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often swing wildly based on binary events like FDA decisions. |
| Valuation risk | Medium / high | It is challenging to assign a fundamental floor to companies with high R&D dependency. |
| Competition risk (Major Pharma) | High | Large competitors can out-spend and out-maneuver Rigel in marketing and distribution. |
| Business quality | Medium | The company has proven commercial capability but maintains a narrow product base. |
| Dividend income | Low / none | No income is returned to shareholders via dividends. |
| Execution risk | Medium / high | Success depends on consistent sales execution and effective clinical development. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 837.18M USD | Price to earnings Ratio 2.84 | 1Y Target Price 64.4 |
Price to earnings Ratio 2.84 | 1Y Target Price 64.4 | ||
Volume (30-day avg) 244.4K shares | Beta 1.24 | 52 Weeks Range 24.95 - 52.60 | Updated Date 11/14/2026 |
52 Weeks Range 24.95 - 52.60 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 15.64 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -12.51% | Avg. Invested days 27 | Today’s Advisory SELL |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Revenue generated from TAVALISSE and REZLIDHIA sales. | The company relies on doctors prescribing their specific drugs to patients. |
| Contract Revenue/Licensing | Upfront payments, milestones, and royalties from partners. | The company sometimes earns money by licensing its drug technology to others. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When After Market | Estimate 0.87 | Actual 0.65 |
Profitability
Profit Margin 106.59% | Operating Margin (TTM) 26.28% |
Management Effectiveness
Return on Assets (TTM) 12.35% | Return on Equity (TTM) 109.18% |
Valuation
Trailing PE 2.84 | Forward PE 9.56 | Enterprise Value 768.83M | Price to Sales(TTM) 2.9 |
Enterprise Value 768.83M | Price to Sales(TTM) 2.9 | ||
Enterprise Value to Revenue 2.67 | Enterprise Value to EBITDA 9.22 | Shares Outstanding 18.83M | Shares Floating 14.99M |
Shares Outstanding 18.83M | Shares Floating 14.99M | ||
Percent Insiders 3.33 | Percent Institutions 90.83 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

